GreyBird Ventures
VC Fund
Concord, United States
GreyBird Ventures is a VC fund in Concord focused on Health Care and Medical. GreyBird Ventures medical technology firm and invests in companies developing products for precision medicine.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 91%
Last updated:
For AI agents: llms.txt
Industries GreyBird Ventures invests in
Stages GreyBird Ventures invests in
Countries GreyBird Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 11 contacts → | |||
Round size
- Seed
- $3M–$5M
- Series A
- $3M–$16M
Investment Focus
Industry
- Health Care 6 (55%)
- Medical 3 (27%)
- Biotechnology 3 (27%)
- Software 2 (18%)
- Health Diagnostics 2 (18%)
Stage
- Series A 4 (36%)
- Seed 2 (18%)
- Funding Round 2 (18%)
- Series C 1 (9%)
- Corporate Round 1 (9%)
Country
- United States 3 (27%)
- Germany 2 (18%)
- China 1 (9%)
- Israel 1 (9%)
- Austria 1 (9%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alice Jacobs
OPerating Advisor
|
OPerating Advisor | Total investments: 0 | Find email | |
Andrew Litt
Advisor
|
Advisor | Total investments: 0 | Find email | |
Anup Raina
Advisor
|
Advisor | Total investments: 0 | Find email | |
Bonnie B Blanchfield
Consultant, Director of Accounting and Finance
|
Consultant, Director of Accounting and Finance | Total investments: 0 | Find email | |
Frank Wu
Advisor
|
Advisor | Total investments: 0 | Find email | |
| See all 11 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| NeuoKaire (formerly Genetika+) is developing a personalized medical testing tool to better treat depression by helping physicians find the best drug therapy for their patients. The Genetika+ test uses innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing. | $10M / Dec 17, 2024 | ||
| NeuoKaire (formerly Genetika+) is developing a personalized medical testing tool to better treat depression by helping physicians find the best drug therapy for their patients. The Genetika+ test uses innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing. | $10M / Series A / Sep 30, 2021 | ||
| Platomics is a Vienna-based company specialized in regulatory automation and the design, development, manufacture and operation of digital in vitro diagnostic medical devices.Our PlatoX platform offers a secure cloud platform, innovative software solutions and a network for the exchange of information, products and services for the IVD industry.We develop compliant, high performance analysis services for genetic testing, which can also be used by manufacturers and labs to set up their own compliant products. | $15.4M / Sep 21, 2021 | ||
| Platomics is a Vienna-based company specialized in regulatory automation and the design, development, manufacture and operation of digital in vitro diagnostic medical devices.Our PlatoX platform offers a secure cloud platform, innovative software solutions and a network for the exchange of information, products and services for the IVD industry.We develop compliant, high performance analysis services for genetic testing, which can also be used by manufacturers and labs to set up their own compliant products. | $16.4M / Series A / Sep 21, 2021 | ||
| Angstrom Bio is biotechnology company that applies novel nucleotide chemistry and machine learning to the study, diagnosis, and treatment of disease. | $3M / Seed / Jun 16, 2021 | ||
| GNA Biosolutions is a molecular technology company based in Martinsried, Germany. Their breakthrough technology, Pulse Controlled Amplification, transforms molecular testing by combining ultrafast nucleic acid amplification with intrinsic sample prep, to enable powerful solutions for the laboratory, on-site applications and the Point of Care. Theirvision is to bring the power of molecular testing, from sample to answer, to everyone, everywhere. | $13.5M / Series C / Aug 06, 2019 | ||
| Jiangxi Zhongke Jiufeng Wisdom Medical Technology Co., Ltd. was established in May 2015. Under the strong support of the Jiangxi Provincial Party Committee Government, Nanchang Municipal Government and the High-tech Zone Government, the former Siemens Northeast Asia (Greater China + Korea) Medical Mr. Wu Wenhui, the president, led the team ofdomestic and international first-class science and technology experts, hospital management experts and industry senior professional managers. | $5M / Corporate Round / Apr 17, 2019 | ||
| Ceres Nanosciences Inc. (“Ceres”) is a privately held life sciences company engaged in the research, development, and commercialization of innovative sample preparation products, based on its proprietary Nanotrap® technology, which captures, enriches and preserves analytes/biomarkers. Early detection of biomarkers, in particular those of lowabundance, is key to the diagnosis and treatment of diseases such as cancer, cardiac, and infectious diseases, resulting in improved patient benefit and reduced health care costs. Ceres has a broad product pipeline of advanced sample collection technologies and diagnostics, funded through federal agency grants and industry collaboration funding. Ceres’ lead product in development is a direct antigen test for the diagnosis of Lyme disease, which will be available commercially in 2015. | $3M / Series A / Feb 02, 2017 | ||
| Atlas5D is a leader in creating solutions to help people with reduced mobility live better and richer lives. These populations range in age from very young to very old; cover a wide variety of conditions, such as multiple sclerosis and Parkinson's; and often do not or cannot use "wearable" sensors. Our product, Echo5D, is theworld's first ambient sensor that sits passively on a shelf and precisely measures human movement and behavior, 24x7, even in the dark. There's nothing to remember, no need to wear any devices, no change in lifestyle, and no photos. By providing insight and quantitative actionable information to caregivers and clinicians, we offer people with reduced mobility the ability to track progression and response of symptoms, and the confidence and opportunity to live independently. Our founders are MIT graduates with experience at McKinsey, Exponent, and Harvard Medical School; mentors include luminaries from Harvard Business School, Siemens, and MIT. Atlas5D is an alumnus of MassChallenge and TechStars. Please visit us at www.atlas5d.com. | $3M / Series A / Feb 01, 2016 | ||
| Its mission is to harness the power of blood bourne miRNAs to the immune system’s response to disease. | Venture - Series Unknown / Jan 01, 2016 | ||
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does GreyBird Ventures invest in?
GreyBird Ventures invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Seed stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is GreyBird Ventures's check size?
GreyBird Ventures typically joins rounds of $3M–$5M at Seed and $3M–$16M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds GreyBird Ventures participates in.
How do I contact GreyBird Ventures?
Public channels for GreyBird Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at GreyBird Ventures?
The team at GreyBird Ventures includes Alice Jacobs (OPerating Advisor), Andrew Litt (Advisor) and Anup Raina (Advisor), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
